Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 27;16(9):1365. doi: 10.3390/v16091365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Net IgG-binding antibody responses [mean fourescence intensity (MFI)-blank] to HBsAg (1:50 dilution) at Month 1 [1 month after TT vaccination; T1_TT-HIV-HBV and T3_TT-HBV], Month 7.5 [two weeks after the last ALVAC and AIDSVAX B/E vaccination; T1_TT-HIV-HBV and T2_HIV], Month 9 [2 weeks after the second HBV vaccination; T1_TT-HIV-HBV and T3_TT-HBV], and Month 13.5 [2 weeks after the third HBV vaccination; T1_TT-HIV-HBV and T3_TT-HBV] in the HVTN 097 participants, stratified by treatment assignment arm. At Month 0, T1_TT-HIV-HBV and T3_TT-HBV received TT; T2_HIV received a placebo. At Months 7.5, 8.5, and 13, T1_TT-HIV-HBV and T3_TT-HBV received HBV; T2_HIV received a placebo. Response rates and numbers of participants are shown at the top of the plot. Responders: red dot; non-responders: open blue triangle.